Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Enduring Legacy of Failed Revascularization Trials.

Journal of the American College of Cardiology·2021
Same author

The Cornelian dilemma† of quitting DAPT.

European heart journal·2021
Same author

Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT-SHOCK Substudy.

Journal of the American Heart Association·2021
Same author

Comparison of risk prediction models in infarct-related cardiogenic shock.

European heart journal. Acute cardiovascular care·2021
Same author

Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.

European heart journal. Cardiovascular pharmacotherapy·2021
Same author

Compared Outcomes of ST-Segment-Elevation Myocardial Infarction Patients With Multivessel Disease Treated With Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Nonculprit Lesions Treated Conservatively and of Those With Low Fractional Flow Reserve Managed Invasively: Insights From the FLOWER-MI Trial.

Circulation. Cardiovascular interventions·2021
Same journal

Effects of Vericiguat on Peripheral Vascular Function and Resting/Exercise Hemodynamics in Patients With Heart Failure With Reduced Ejection Fraction: An Exploratory Pilot Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Norepinephrine Versus Dopamine as Vasoactive Therapy in Cardiogenic Shock: Association With 28-Day Mortality in a Retrospective Cohort Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

ABCD-GENE Score and Bleeding in Post-PCI Patients: Implications for Guided De-Escalation of Antiplatelet Therapy.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Alterations of Platelet MicroRNAs Associated With Dapagliflozin Treatment in Individuals With Type 2 Diabetes Mellitus.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Comparative Effectiveness of Renin-Angiotensin System Inhibitors in Heart Failure With Nonreduced Ejection Fraction: A Multicenter Cohort Study.

Journal of cardiovascular pharmacology and therapeutics·2026
Same journal

Shared Genetic Liability Between Heart Failure and Myocardial Infarction Revealed by Genome-Wide Cross-Trait Analysis.

Journal of cardiovascular pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Platelet function testing and implications for clinical practice.

Jean-Philippe Collet1, Gilles Montalescot

  • 1Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France.

Journal of Cardiovascular Pharmacology and Therapeutics
|September 2, 2009
PubMed
Summary
This summary is machine-generated.

Platelet function testing assesses response to antiplatelet drugs like aspirin. Low response correlates with ischemic events, but clinical trials are needed to confirm if adjusting therapy improves outcomes.

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Related Experiment Videos

Last Updated: Jun 20, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Platelets are central to atherothrombotic disease pathophysiology.
  • Inappropriate platelet activation contributes to thrombosis and ischemic events.
  • Antiplatelet therapy is crucial for managing these conditions.

Purpose of the Study:

  • To evaluate the role of platelet function testing in monitoring antiplatelet therapy response.
  • To investigate the correlation between platelet function assay results and clinical outcomes.
  • To determine if tailoring antiplatelet therapy based on platelet function improves patient outcomes.

Main Methods:

  • Review of current literature on platelet function assays and antiplatelet therapy.
  • Analysis of correlations between different platelet function assays.
  • Examination of clinical trial data regarding antiplatelet therapy response and outcomes.

Main Results:

  • Variability in response to aspirin and P2Y(12) antagonists may stem from incomplete pathway inhibition.
  • Low responsiveness to antiplatelet therapy, as measured by assays, is linked to increased ischemic event rates.
  • Correlations between assays are modest, and defining suboptimal response lacks concordance.

Conclusions:

  • Platelet function testing shows potential for monitoring antiplatelet therapy but requires further validation.
  • Clinical trials are necessary to establish whether guided therapy adjustments improve outcomes.
  • Broader clinical application of platelet function testing hinges on proven outcome benefits.